Altura Medical has grabbed $6 million in new venture equity financing, according to a regulatory filing.
The California-based company, which is developing a stent graft to treat abdominal aortic aneurysms, has generally kept a low profile in recent years. And Altura says little in its April 10 SEC filing about the money raised, other than noting that it is pursuing an overall financing of about $10 million, including the new funding.
Altura was chattier back in 2010 when it raised a $20 million Series A round. The company issued a formal announcement and then-acting president and CEO George Wallace called the new funding "a high level of investor confidence in the Altura opportunity." New Leaf Venture Partners led that round, which included Advanced Technology Ventures and SV Life Sciences.
Altura has previously termed its device and methods under development to treat abdominal aortic aneurysms as a less invasive treatment alternative designed to improve survival rates and reduce recovery times. The company competes in a space that already has rivals much further along. Last October, for example, the FDA granted coveted pre-market approval to TriVascular's Ovation abdominal stent graft, which has had a CE mark since 2010. And that product competes with similar offerings from Johnson & Johnson ($JNJ), W.L. Gore and others.